Skip to main content
SpringerLink
Log in

Stimulant Dependence

  • Chapter
  • First Online:
Substance Use Disorders

  • 1474 Accesses

Abstract

Central nervous system stimulants are a class of drugs that speed up physical and mental processes. They include the amphetamines, cocaine, methylphenidate, phentermine, modafinil, bath salts, flakka, and caffeine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National survey on drug use and health: trends in prevalence of various drugs for ages 12 or older, ages 12 to 17, ages 18 to 25, and ages 26 or older. National Institute on Drug Abuse (NIDA). https://www.drugabuse.gov/national-survey-drug-use-health. 2015.

  2. Amphetamines. Center for Substance Abuse Research (CESAR)/University of Maryland. http://www.cesar.umd.edu/cesar/drugs/amphetamines.asp

  3. Various stimulant drugs show continuing gradual declines among teens in 2008, most illicit drugs hold steady. Michigan News/University of Michigan. http://ns.umich.edu/new/releases/6882-various-stimulant-drugs-show-continuing-gradual-declines-among-teens-in-2008-most-illicit-drugs-hold-steady. December 15, 2008.

  4. Dubuc B. The brain from top to bottom. McGill University. http://thebrain.mcgill.ca/flash/i/i_03/i_03_m/i_03_m_par/i_03_m_par_heroine.html#drogues. May 2012.

  5. Christian L. Drugs of abuse. In: Katzung BG, Trevor AJ, editors. Basic and clinical pharmacology. 13th ed. New York: McGraw-Hill Education; 2014. p. 552–6.

    Google Scholar 

  6. O’Brien RC. The encyclopedia of drug abuse. Facts on File: New York; 1984.

    Google Scholar 

  7. Wilford BB, editor. Major drugs of abuse. In: Drug abuse: a guide for the primary care physician. Chicago: American Medical Association; 1981. p. 21–84.

    Google Scholar 

  8. Shlafer M, Marieb EN. Substance use and misuse. In: The nurse, pharmacology and drug therapy. Redwood City: Addison-Wesley; 1989. p. 509–28.

    Google Scholar 

  9. Anglin MD, Perrochet B, Burke C, Stamper E, Dawud-Noursi S. History of the methamphetamine problem. J Psychoact Drugs. 2011:137–41.

    Google Scholar 

  10. Methamphetamine. Center for Substance Abuse Research (CESAR)/University of Maryland. http://www.cesar.umd.edu/cesar/drugs/meth.asp

  11. Methamphetamine. National Institute on Drug Abuse (NIDA). https://www.drugabuse.gov/drugs-abuse/methamphetamine. February 2017.

  12. Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician. 2007;76(8):1169–74.

    PubMed  Google Scholar 

  13. Handly N. Amphetamine toxicity. Medscape. December 16, 2016.

    Google Scholar 

  14. Tennant FS. Cocaine withdrawal step by step. Emergency Medicine. 1987;65–68.

    Google Scholar 

  15. Milhorn HT. Chemical dependence: diagnosis, treatment, and prevention. New York: Springer; 1990.

    Book  Google Scholar 

  16. Vereby K, Gold MS. From coca leaves to crack: the effects of dose and routes of administration on abuse liability. Psychiatr Ann. 1988;18:513–20.

    Article  Google Scholar 

  17. Wyatt RJ, Karourn F, Suddath R, Hitri A. The role of dopamine in cocaine use and abuse. Psychiatr Ann. 1988;18:531–4.

    Google Scholar 

  18. Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW, editors. Principles of pharmacology: the pathophysiological basis of drug therapy. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, Wolters Kluwer; 2011.

    Google Scholar 

  19. Gold M. Crack abuse: its implications and outcomes. Resid Staff Physician. 1987;33:45–53.

    Google Scholar 

  20. Bouknight LG. Cocaine – a particularly addicting drug. Postgrad Med. 1988;83:115–31.

    Article  CAS  PubMed  Google Scholar 

  21. Gottheil E, Weinstein SP. Cocaine risks: a review. Fam Pract Recertification. 1983;5:78–90.

    Google Scholar 

  22. Garvin FH. Chronic neuropharmacology of cocaine: progress in pharmacotherapy. J Clin Psychiatry. 1988;49:11–6.

    Google Scholar 

  23. Dackis CA, Gold MS. Psychopharmacology of cocaine. Psychiatr Ann. 1988;18:528–30.

    Article  Google Scholar 

  24. The health effects of cocaine use and abuse: short-term and long-term effects. VeryWell. https://www.verywell.com/the-health-effects-of-cocaine-abuse-66706. November 16, 2016.

  25. DrugFacts: cocaine. National Institute on Drug Abuse (NIDA). https://www.drugabuse.gov/publications/drugfacts/cocaine. June 2016.

  26. Cregler LL, Mark H. Medical complications of cocaine abuse. N Engl J Med. 1986;345:1495–500.

    Article  Google Scholar 

  27. Miller GW. The cocaine habit. Am Fam Physician. 1985;31:173–6.

    PubMed  Google Scholar 

  28. Bouknight LG. Cocaine – a particularly addicting drug. Postgrad Med. 1988;83:115–31.

    Article  CAS  PubMed  Google Scholar 

  29. Brower KJ, Paredes A. Cocaine withdrawal. Arch Gen Psychiatry. 1987;44(3):297–8.

    Article  CAS  PubMed  Google Scholar 

  30. Dittmar PK, Olmedo R. An evidence-based approach to cocaine-associated emergencies. Emerg Med. 2008;10(1):1–20.

    Google Scholar 

  31. Dwyer BJ, editor. Cocaine: helping patients avoid the end of the line. Emerg Med Rep. 1985;6:17–26.

    Google Scholar 

  32. Ritalin. Center for Substance Abuse Research (CESAR). University of Maryland. http://www.cesar.umd.edu/cesar/drugs/ritalin.asp. 2013.

  33. Ritalin Fast Facts. National Drug Intelligence Center (NDIC). http://www.justice.gov/archive/ndic/pubs6/6444. September 2003.

  34. Methylphenidate. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682188.html. February 15, 2016.

  35. Phentermine. Drugs.com. http://www.drugs.com/pro/phentermine.html. 2015.

  36. Biaggioni I, Roberson D. Adrenoceptor agonists and sympathomimetic drugs. In: Bertram GK, Trevor AJ, editors. Basic and clinical pharmacology. 13th ed. New York: McGraw-Hill; 2015.

    Google Scholar 

  37. The effects of bath salts use. Drug Abuse. http://drugabuse.com/library/the-effects-of-bath-salts-use

  38. Glatter R. Flakka: the new designer drug you need to know about. Forbes. http://www.forbes.com/sites/robertglatter/2015/04/04/flakka-the-new-drug-you-need-to-know-about/#209ed1ba20bf. April 4, 2015.

  39. Caffeine content for coffee, tea, soda and more. Mayo Clinic. http://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/caffeine/art-20049372. May 13, 2014.

  40. Kotz D. FDA warns against dangers of caffeine powder. Boston Globe. July 23, 2014.

    Google Scholar 

  41. Gilbert SG. Caffeine. Toxipedia. http://www.toxipedia.org/display/toxipedia/Caffeine. June 13, 2012.

  42. DSM-5. Diagnostic and statistical manual of mental disorder. In: American Psychiatric Association. 5th ed. Arlington: American Psychiatric Publishing; 2013.

    Google Scholar 

  43. Caffeine: how much is too much? Mayo Clinic. http://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/caffeine/art-20045678. April 14, 2014.

  44. Schueler SJ, Beckett JH, Gettings DS. Caffeine overdose. Treatment. FreeMD. http://www.freemd.com/caffeine-overdose/treatment.htm. May 23, 2011.

Download references

Author information

Authors and Affiliations

  1. East Central HealthNet Family Medicine Residency Program, Meridian, Mississippi, USA

    H. Thomas Milhorn MD, PhD (Director, Didactics Section, Formerly Professor of Family Medicine, Professor of Physiology and Biophysics, and Associate Professor of Psychiatry and Human Behavior)

  2. University of Mississippi School of Medicine, Jackson, Mississippi, USA

    H. Thomas Milhorn MD, PhD (Director, Didactics Section, Formerly Professor of Family Medicine, Professor of Physiology and Biophysics, and Associate Professor of Psychiatry and Human Behavior)

Authors
  1. H. Thomas Milhorn MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Milhorn, H.T. (2018). Stimulant Dependence. In: Substance Use Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-63040-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63040-3_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63039-7

  • Online ISBN: 978-3-319-63040-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation